准心脏:阿尔茨海默病预防的新轴线
Lawrence I Heller1, Allison S Lowe1, Thaís Del Rosario Hernández1
1Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island, United States.
bioRxiv : the preprint server for biology
|February 20, 2025
概括
心脏药物可以通过抑制氨酸-NFAT通路来预防阿尔茨海默病. 将它们与环素A结合,会产生协同效应,有可能同时治疗这两种疾病,并减少副作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 像环素A这样的卡尔西尼乌林抑制剂对预防阿尔茨海默氏病有很大的前景.
- 一个神经网络模型,Z-LaP追踪器,在斑马鱼幼虫中鉴定出一种独特的行为特征,这种特征是由氨酸抑制剂诱导的.
研究的目的:
- 使用Z-LaP追踪器选FDA批准的药物,以检测类似环素A的行为特征.
- 研究心脏药物作为阿尔茨海默病治疗药物的潜力.
- 为了探索结合心脏药物与环素A的协同效应.
主要方法:
- 利用Z-LaP追踪器神经网络模型在斑马鱼幼虫中进行药物查.
- 选了FDA批准的药物库,以识别那些模仿环素A行为效应的药物.
- 进行了与精选的心脏药物和环素A的双重管理研究.
主要成果:
- 确定了65种具有环素A类特征的药物,包括14种心脏药物.
- 观察到许多已确定的心脏药物抑制了氨酸-NFAT通路.
- 在将低剂量心脏药物与环素A结合时发现了协同效应,增强了行为结果.
结论:
- 选择心脏药物,特别是那些抑制氨酸-NFAT通路的药物,可能有效预防或治疗阿尔茨海默病.
- 低剂量环素A与特定的心脏药物的同时使用,为同时治疗阿尔茨海默病和心血管功能障碍提供了潜在的策略.
- 西姆瓦斯塔丁,伊尔贝萨坦,基洛斯塔,多克萨佐辛和尼比沃被确定为阿尔茨海默病治疗进一步研究的有希望的候选人.
相关概念视频
01:22Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
01:26Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429
01:17Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
01:27Psychoneuroimmunology: Cardiovascular Disease
25
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
25
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:27Regulation of the Cardiovascular System
342
The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
342